After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries
You may also be interested in...
Korea’s Boryung Licenses Hypertension Therapy Kanarb To China’s Harbin Gloria
In its latest deal for the sale of its hypertension Kanarb product outside Korea, Boryung signed a 10-year deal with China from 2018.
Boryung Pharma And Fellow Korean Firms Sign A Handful Of Overseas Deals – Bio Korea 2013
Boryung, Taejoon, Ilyang and other Korean pharma signed agreements to bring their products to the Middle East, Mongolia and Japan.
Korea's Boryung Takes Hypertension Drug Kanarb Beyond Korea With Stendhal Deal
SEOUL - Boryung Pharma signed a licensing agreement with Stendhal International, a Mexico-based company, to supply the South Korean company's angiotensin receptor blocker Kanarb (fimasartan) for $22.6 million, marking the first time Kanarb will be sold outside of Korea